Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study by Pires da Silva, Ines, PhD, Ahmed, Tasnia, MSc, Reijers, Irene L M, MD, Weppler, Alison M, MD, Betof Warner, Allison, MD, Patrinely, James Randall, MD, Serra-Bellver, Patricio, MD, Allayous, Clara, PhD, Mangana, Joanna, MD, Nguyen, Khang, MD, Zimmer, Lisa, MD, Trojaniello, Claudia, MD, Stout, Dan, MD, Lyle, Megan, MD, Klein, Oliver, MD, Gerard, Camille L, MD, Michielin, Olivier, Prof, Haydon, Andrew, MD, Ascierto, Paolo A, Prof, Carlino, Matteo S, PhD, Lebbe, Celeste, Prof, Lorigan, Paul, Prof, Johnson, Douglas B, MD, Sandhu, Shahneen, MD, Lo, Serigne N, PhD, Blank, Christian U, Prof, Menzies, Alexander M, PhD, Long, Georgina V, Prof

Get full text